This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Daniel DeOliveira, Ph.D.
Director of Pharmaceutical Sciences & Manufacturing at Genocea Biosciences


Dr. Daniel B. DeOliveira has 20 plus years of contributing to drug discovery and pharmaceutical science primarily in the area of peptides and peptidomimetics. He has led drug discovery efforts focusing on rare diseases, oncology and nuclear medicine. He received his PhD in Medicinal Chemistry from Boston University, under the leadership of Prof. Richard Laursen. He went on to do his initial immunology studies, to MIT, designing tight binding MHC antigens that could function as synthetic T-cell antigens. After several years at MIT, Dr. DeOliveira took a position in the private sector at Dyax Corp. where he established and managed a peptide research group to meet the needs of peptide based projects at Dyax Corp, a company focused on rare hereditary diseases. Dr. DeOliveira’s research while at Dyax contributed to the eventual FDA approval of Kalbitor (Ecallantide, DX-88) a treatment for hereditary angioedema. Following Dyax, he took an opportunity at Ipsen Bioscience, a mid-size pharmaceutical company, with a strong research program focused on peptides as therapeutic drugs for rare diseases. While at Ipsen, he worked on several peptide-related projects including a Ghrelin agonist (Relamorelin™, BIM-28131) and a MC4R agonist (Setmelanotide™, BIM-22943) both currently in Phase-3 clinical studies.  He also led a nuclear medicine program aimed at targeting Neuroendocrine Tumors, where he developed a successful, novel approach to solve the kidney rate limiting effects of radio-theranostics (PRRT) and also successfully designed a peptide / small molecule combo to target Neuroendocrine tumors via non-SSTR mechanism. He is currently Director of Pharmaceutical Sciences & Manufacturing at Genocea, working on T-cell immunity aiming to successfully develop neoantigen cancer vaccines.

He has been awarded several patents based on peptide therapeutics and has several more patent applications under review by the US patent office. He has over two dozen peer-reviewed publications, been a speaker at several conferences and has been the recipient of several Ipsen awards. He has been an organizer of Pep-Talks in the Boston Cambridge area, as well as Cambridge Peptide Showcase East. He currently is serving as a Board Member and President of the UMass Dartmouth Alumni Association.

Agenda Sessions

  • Peptides for T cell Therapy